DELCATH SYS INC (DCTH)
Health Care · Interventional oncology / liver-directed cancer therapy · NASDAQ
Interventional oncology company bringing a catheter-based chemotherapy delivery system to market for treating liver cancers, anchored by the newly FDA-approved HEPZATO kit for uveal melanoma metastases.
What DELCATH SYS INC does
Delcath Systems is an interventional oncology company focused on treating cancers primary or metastatic to the liver. The company's lead product, HEPZATO KIT (melphalan/hepatic delivery system), was FDA-approved in August 2023 for adult patients with uveal melanoma with unresectable hepatic metastases. HEPZATO combines a chemotherapy drug with a proprietary catheter-based delivery device to enable targeted treatment to the liver, with commercial launch beginning January 2024. The company also markets CHEMOSAT, its hepatic delivery system device (without drug), in Europe.
Themes: Interventional oncology, Liver cancer treatment, Orphan drugs / rare cancers, Uveal melanoma, Hepatocellular carcinoma, Metastatic liver cancer
Fundamentals
- Price$17.14 as of 2026-08-21 close
- Market cap$595M as of 2026-08-21
- 1-year return+64.6% 2025-08-21 close $10.41 → 2026-08-21 close $17.14
- P/E1117.60 as of 2026-08-24
- Net margin+0.6% as of 2026-08-24
- Gross margin+87.0% as of 2026-08-24
- ROE+0.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+35.9% as of 2026-08-24
- Revenue CAGR (3y)+215.3% SEC XBRL
- Beta0.60 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How DCTH compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How DELCATH SYS INC looks technically
DELCATH SYS INC (DCTH) is trading 57.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 67 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 7 trading days ago. It is 1.6% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 57.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +57.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.52 | $13.52 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.87 | $10.87 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 13.74. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 67 trading days ago — a "golden cross", a bullish long-term signal | 67 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control | 38.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 68.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($12.43 to $17.42) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.42 | $17.42 |
|---|---|---|
| From the 52-week high | it is 1.6% below its 52-week high (its highest price of the past year) | -1.6% |
| Above the 52-week low | it is 111.1% above its 52-week low (its lowest price of the past year) | +111.1% |
| Below the 52-week high | it is 1.6% below its highest point of the past year | 1.6% |
| Since a 20-day breakout | it made a new 20-day high about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day high about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $7210.00 (set on 2018-09-19) | $7210.00 |
| Given back of the 52-week move | over the past year its closes ranged ($8.19 to $17.36), and it has given back only a small part of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.40 to $11.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.4% |
| From the all-time high | it is 99.8% below its all-time high | -99.8% |
| Nearest price level | it is trading 1.4% below a resistance level at $17.39 — a price it turned at twice since 2025-06-06, most recently on 2026-08-11. Since 2024-08-21 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $2.25 (set on 2023-11-14) | $2.25 |
| Above the all-time low | it is 661.8% above its all-time low | +661.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7211 between its high and its low — about 4.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7211 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.40 and $19.48 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.40 – $14.94 – $19.48 |
| Typical daily range (% of price) | its price moves about 4.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.2% |
| Stretch from the 200-day average | it is trading 8.7 daily ranges above its 200-day average price (57.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.85× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 11.1% above the previous close 11 sessions ago and has not traded back through the level it left behind at 12.63 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +11.1% |
| Gap filled | a 2.6% gap down opened on 2026-07-17 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 31.5 percentage points (the stock gained 33.8% while the market gained 2.3%) | +31.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 46.6 percentage points (the stock gained 49.7% while the market gained 3.1%) | +46.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 64.2 percentage points (the stock gained 75.3% while the market gained 11.1%) | +64.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 44.2 percentage points (the stock gained 64.6% while the market gained 20.5%) | +44.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 34% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.8% of the share price. | +34.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 48% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.60 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +47.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $16.40 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.5% |
Price levels it has turned at before
DCTH last closed at $17.14 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $17.39 | Resistance | 1.4% above the last close | turned there twice · 2025-06-06 to 2026-08-11 |
| $15.62 | Support | 8.9% below the last close | turned there twice · 2025-02-11 to 2025-05-30 |
| $13.37 | Support | 22.0% below the last close | turned there twice · 2024-12-16 to 2025-08-06 |
| $12.84 | Support | 25.1% below the last close | turned there four times · 2024-11-08 to 2025-10-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $13.74.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $14.46 and $16.02 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $17.42.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$24.00 range $21.00 – $32.00; median $22.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DCTH
- Consensus EPS estimate-$0.07 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["HEPZATO is a recently approved drug with limited commercial history and clinical adoption; commercial success depends on healthcare provider awareness, patient identification, and reimbursement","Company operates in narrow oncology indications with orphan drug designations; limited patient populations and market size concentration create revenue volatility risk","Medical device and combination product regulatory complexities; manufacturing and supply chain risks could disrupt commercialization, and company faces potential obsolescence or competitive pressure from alternative liver-directed therapies"]
What changed in the latest 10-Q
AI-assisted comparison of DCTH's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to Form 10-K for fiscal year ended December 31, 2025 filed February 26, 2026 (newer filing, 2026-05-07)
- Added forward-looking statement bullet: 'our expectations and timing related to our ongoing and planned clinical trials evaluating HEPZATO for the treatment of other metastatic cancers' (newer filing, 2026-05-07)
- Added forward-looking statement bullet: 'our ability to successfully source components of CHEMOSAT, the HEPZATO KIT, and future products, if any, and enter into manufacturing and supplier contracts' (newer filing, 2026-05-07)
- Removed:
- Removed reference to Form 10-K for fiscal year ended December 31, 2024 filed March 6, 2025 (older filing, 2025-11-04)
- Removed forward-looking statement bullet: 'our expectations and timing related to our Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic colorectal cancer' (older filing, 2025-11-04)
- Removed forward-looking statement bullet: 'our expectations and timing related to our Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic breast cancer' (older filing, 2025-11-04)
- Removed forward-looking statement bullet: 'our expectations that the publication of additional data from our Phase 3 FOCUS Trial, or any other trial that we initiate in the future, will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States' (older filing, 2025-11-04)
- Reworded:
- Changed 'the HEPZATO KIT for the treatment of metastatic hepatic dominant uveal melanoma' to 'the HEPZATO for the treatment of metastatic hepatic dominant uveal melanoma' (removed 'KIT' in this context, newer filing 2026-05-07)
- Changed 'our ability to successfully source components of CHEMOSAT, HEPZATO KIT, and future products, if any, and enter into supplier contracts' to 'our ability to successfully source components of CHEMOSAT, the HEPZATO KIT, and future products, if any, and enter into manufacturing and supplier contracts' (added 'the' and 'manufacturing', newer filing 2026-05-07)
- Changed 'our ability to source melphalan and other critical components necessary to manufacture HEPZATO KIT' to 'our ability to source melphalan and other critical components necessary to manufacture the HEPZATO KIT' (added 'the', newer filing 2026-05-07)
- Changed 'our ability to successfully manufacture CHEMOSAT and HEPZATO KIT' to 'our ability to successfully manufacture CHEMOSAT and the HEPZATO KIT' (added 'the', newer filing 2026-05-07)
- Changed 'our expectations that the results of any current or future clinical trial that we or any collaborator initiates will support increased clinical adoption of and reimbursement for our products' (generic language in newer filing 2026-05-07 vs. specific Phase 2 and Phase 3 trial references in older filing 2025-11-04)
- Notes:
- Older filing text appears truncated at end of Company Overview section; full comparison of that section not possible
- Changes reflect shift from specific ongoing Phase 2 trials (colorectal and breast cancer) in older filing to broader 'ongoing and planned clinical trials' language in newer filing
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days2 buys ($150328) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-03-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DCTH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding DCTH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,789,778
- Reported value $25,889,144
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DCTH had 2,532,559 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DCTH had 7.30% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.23 days to cover at the same settlement.
- Reported short interest (shares) 2,532,559
- Short interest (% of shares outstanding) 7.30%
- Prior settlement (shares) 2,694,391
- Reported change -6.01%
- Days to cover (reported) 7.23
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sirtex Medical (Varian/Siemens Healthineers)
- Boston Scientific (BSX)
- Medtronic (MDT)
- AngioDynamics (ANGO)
- BD (Becton, Dickinson and Company) (BDX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DCTH vs…
DCTH ranks in…
Frequently asked questions
What does DELCATH SYS INC (DCTH) do?
Delcath Systems is an interventional oncology company focused on treating cancers primary or metastatic to the liver. The company's lead product, HEPZATO KIT (melphalan/hepatic delivery system), was FDA-approved in August 2023 for adult patients with uveal melanoma with unresectable hepatic metastases. HEPZATO combines a chemotherapy drug with a proprietary catheter-based delivery device to enable targeted treatment to the liver, with commercial launch beginning January 2024.
What sector is DELCATH SYS INC (DCTH) in?
DELCATH SYS INC (DCTH) is classified in the Health Care sector. Its industry is Interventional oncology / liver-directed cancer therapy. It trades on NASDAQ.
Who are DELCATH SYS INC's (DCTH) competitors?
Notable peers of DELCATH SYS INC (DCTH) include Sirtex Medical (Varian/Siemens Healthineers), Boston Scientific, Medtronic, AngioDynamics and BD (Becton, Dickinson and Company). This peer set is informational only — not financial advice.
Is DELCATH SYS INC (DCTH) overbought or oversold right now?
DELCATH SYS INC (DCTH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DCTH come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.